Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage

2014 ◽  
Vol 75 (2) ◽  
pp. 273-279 ◽  
Author(s):  
Katsuya Makihara ◽  
Sayaka Azuma ◽  
Nobuyuki Kawato ◽  
Hiroyuki Ueno ◽  
Izumi Nakata
2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 68-68
Author(s):  
Katsuya Makihara ◽  
Sayaka Azuma ◽  
Hiroko Hasegawa ◽  
Masataka Ikeda ◽  
Kazumasa Fujitani ◽  
...  

68 Background: Irinotecan (CPT-11) is widely used for the treatment of patients with gastrointestinal cancer. However, CPT-11 can cause severe neutropenia and diarrhea.It has been reported that the AUC of SN-38, an active metabolite of CPT-11, correlated with Pre-treatment serum total bilirubin level (PTB), but there is no criteria of dose setting based on the PTB. Therefore, we retrospectively searched the PTB which can serve as an indicator for dose setting of CPT-11. Methods: We investigated the incidence of neutropenia and diarrhea at the first 28 days in patients with gastrointestinal cancer who were administered CPT-11 alone in Osaka National Hospital from June 2006 to July 2013. Correlation between PTB and grade 3-4 neutropenia or diarrhea were assessed. When toxicity of correlation exists, ROC (receiver operating characteristic) analysis was conducted to explore the cut-off value of the PTB. In addition, the incidence of febrile neutropenia (FN) in the cut-off value was compared. Results: 87 patients were analyzed. Of these, 65 were gastric cancer, 22 were colorectal cancer. Although PTB was significantly higher in patients who experienced grade 3-4 neutropenia than those who didn’t (p<0.001), PTB was not associated with grade 3-4 diarrhea. As the results of ROC analysis, cut-off value of PTB associated with grade 3-4 neutropenia was determined to 0.8 mg/dL. The incidence of FN was significantly higher in 20% of patients with PTB ≥ 0.8 mg/dL compared with 1.6% of patients with PTB < 0.8 mg/dL (OR: 15.5, p=0.01). On the other hand, in subgroup analysis showed no difference in the incidence of FN and neutropenia in patients whose dose was less than 100 mg/m². Conclusions: PTB was a predictive marker for CPT-11-induced severe neutropenia and FN. Results of this study suggested needs of dose reduction to less than 100 mg/m2 in patients with PTB ≥ 0.8mg/dL.


2012 ◽  
Vol 45 (4-5) ◽  
pp. 289-292 ◽  
Author(s):  
Byoung-Jin Park ◽  
Jae-Yong Shim ◽  
Hye-Ree Lee ◽  
Hee-Taik Kang ◽  
Jung-Hyun Lee ◽  
...  

2015 ◽  
Vol 7 ◽  
pp. e2015060 ◽  
Author(s):  
Said Y ALkindi ◽  
Anil Pathare ◽  
Salam Alkindi

Background: We explored the potential relationship between steady state serum bilirubin levels and the incidence of cholelithiasis in the context of UGT1A1 gene A(TA)nTAA promoter polymorphism in Omani sickle cell anemia (SCA) patients, homozygotes for African (Benin and Bantu) and Arab-Indian bS haplotypes, but sharing the same microgeographical environment and comparable life style factors. Methods: 136 SCA patients were retrospectively studied in whom imaging data including abdominal CT scan, MRI or Ultrasonography was routinely available. Available data on the mean steady state hematological/biochemical parameters (n=136),  bs haplotypes(n=136), a globin gene status (n=105) and UGT1A1 genotypes(n=133) were reviewed from the respective medical records. Results: The mean serum total bilirubin level was significantly higher in the homozygous UGT1A1(AT)7 group as compared to  UGT1A1(AT)6 group. Strikingly, cholelithiasis was not influenced by age, gender, alpha globin genotype or bS haplotypes in this SCA cohort. Conclusion: As observed in other population groups, the UGT1A1 (AT)7 homozygosity was significantly associated with raised serum total bilirubin level, but the prevalence of gallstones in the Omani SCA patients was not associated with a thalassaemia, UGT1A1 polymorphism, or bs haplotypes. 


2013 ◽  
Vol 17 (6) ◽  
pp. 464-469 ◽  
Author(s):  
Hiroyuki Moriya ◽  
Katsuhiko Saito ◽  
Nuala Helsby ◽  
Shigekazu Sugino ◽  
Michiaki Yamakage ◽  
...  

Author(s):  
Shenghua Zhou

The present study evaluated risk factors related to persistent atrial fibrillation (AF) at discharge (AF-d) and recurrentatrial fibrillation (rAF) and all-cause death after the maze IV procedure. Two hundred nineteen patients (63 female,aged 52.5 ± 8.8 years) with valve disease and persistent AF undergoing valve surgery and the maze IV procedure in our center between 2015 and 2016 were included. Baseline demographic and clinical data were obtained by review of medical records. The median follow-up period was 27 months (interquartile range 21–34 months) in our patient cohort.The primary end point was all-cause death. The secondary end point was AF-d or rAF. rAF is defined as AF recurrenceat 3 months or later after the procedure. Twenty-eight patients (12.8%) died during follow-up. Multiple logistic regression analysis showed that thrombocytopenia, elevated serum total bilirubin level, a larger right atrium, AF-d, and rAF were independent determinants for all-cause death after the maze IV procedure after adjustment for age, sex, and clinical covariates, including New York Heart Association class III/IV disease, hypertension, and aortic regurgitation, while valvular disease duration and left atrial diameter greater than 80.5 mm were independent determinants for AF-d, and thrombocytopenia, elevated serum total bilirubin level, higher mean pulmonary artery pressure, and AF-d were independent predictors for rAF. In conclusion, thrombocytopenia, elevated serum total bilirubin level, an enlarged right atrium, AF-d, and rAF are independent predictors of all-cause death in patients undergoing the maze IV procedure.


Sign in / Sign up

Export Citation Format

Share Document